Sign In
Buy NBIX
$176.41
+0.640 (+0.364%)
At Close: Jul 27, 2026
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
11:07am, Wednesday, 23'rd Oct 2024
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neurocrine: A Buy Amid CNS Pipeline Growth And Ingrezza's Strength (Rating Upgrade)
07:42am, Thursday, 10'th Oct 2024
Neurocrine Biosciences' Ingrezza has grown into a multibillion-dollar drug, but the company's stock has underperformed the S&P 500 since 2019. Neurocrine's NBI-1117568 demonstrated encouraging Phase 2
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results
04:01pm, Wednesday, 09'th Oct 2024
Conference Call and Webcast Scheduled for Wednesday, October 30 SAN DIEGO , Oct. 9, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third qua
KINECT®-HD2 Is the First Prospective Clinical Trial to Include Patients Taking Antipsychotic Medication in a Study Evaluating a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor for the Treatment o
Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit
04:01pm, Thursday, 19'th Sep 2024
SAN DIEGO , Sept. 19, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit at 11:00 a.m.
Neurocrine's experimental drug misses primary goal in schizophrenia trial
04:31pm, Thursday, 12'th Sep 2024
Neurocrine Biosciences said its experimental drug did not achieve the primary goal in a mid-stage trial aimed at improving cognitive function in patients with schizophrenia.
Second Phase 2 Study for Luvadaxistat Fails to Meet Primary Endpoint as Potential Treatment for Cognitive Impairment Associated with Schizophrenia Results Confounded by Variability in Cognition Measur
Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference
04:01pm, Tuesday, 10'th Sep 2024
SAN DIEGO , Sept. 10, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the 2024 Cantor Global Healthcare Conference in New York at 3:05 p.m.
Why Neurocrine Biosciences Stock Was Tumbling This Week
07:41am, Friday, 30'th Aug 2024
The biotech released the results of phase 2 clinical trial of its investigational schizophrenia drug. One of the four doses clearly performed well.
Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock
01:22pm, Thursday, 29'th Aug 2024
Wednesday, Neurocrine Biosciences, Inc. (NASDAQ: NBIX) topline data for its Phase 2 clinical study of NBI-1117568 (NBI-‘568) in adults with schizophrenia.
Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results
12:37pm, Thursday, 29'th Aug 2024
Though data from a mid-stage study shows that treatment with NBIX's schizophrenia drug is effective, results lag behind drugs being developed by its peers.
Neurocrine: Buying Opportunity After Stock Price Drop On Schizophrenia Data
05:22pm, Wednesday, 28'th Aug 2024
Despite Neurocrine Biosciences, Inc. muscarinic receptor drug NBI-'568 not surpassing competitors in Schizophrenia, several other drugs of the same type are being developed for large market indication
Neurocrine Biosciences to Participate at Investor Conferences in September
04:05pm, Wednesday, 28'th Aug 2024
Morgan Stanley 22nd Annual Global Healthcare Conference on September 4 in New York 2024 Wells Fargo Healthcare Conference on September 5 in Boston SAN DIEGO , Aug. 28, 2024 /PRNewswire/ -- Neurocrine
Neurocrine Biosciences: Disappointing Data From A Key Readout Hits The Stock Hard
01:11pm, Wednesday, 28'th Aug 2024
Neurocrine Biosciences posted disappointing Phase II data for its schizophrenia drug NBI-1117568, driving a steep fall in the share price. NBI-568 came up short in terms of PANSS reduction, with a 7.5
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
11:16am, Wednesday, 28'th Aug 2024
Wednesday, Neurocrine Biosciences, Inc. NBIX topline data for its Phase 2 clinical study of NBI-1117568 (NBI-‘568) in adults with schizophrenia.
